-+ 0.00%
-+ 0.00%
-+ 0.00%

ALDEYRA THERAPEUTICS ACHIEVES PRIMARY ENDPOINT IN PHASE 3 DRY EYE DISEASE CHAMBER TRIAL OF REPROXALAP AND PLANS NDA RESUBMISSION

Reuters·05/05/2025 22:34:30

Please log in to view news